Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Vijay O. Bhargava"'
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 32:419-439
Leflunomide is a pyrimidine synthesis inhibitor used in the treatment of rheumatoid arthritis. Data from two clinical studies were used to establish a population pharmacokinetic (PPK) model for the active metabolite (M1) of leflunomide in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c055ec736ac3b7e04858bea1093a280
https://doi.org/10.1007/s10928-005-0049-8
https://doi.org/10.1007/s10928-005-0049-8
Autor:
Pierre Hardy, G. Montay, Ramon Vargas, Violette Leclerc, Thomas Marbury, Jun Shi, Marshall Sack, Vijay O. Bhargava, Sunny Chapel, Suzanne K. Swan, Jeffrey S. Barrett, Bruno Leroy
Publikováno v:
The Journal of Clinical Pharmacology. 44:234-244
The pharmacokinetics and safety of the ketolide telithromycin were evaluated in two separate studies after single and repeat oral dosing in patients with varying degrees of renal impairment and in subjects with normal renal function. The single-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dcdc9d8006513e6175d549a822c494b
https://doi.org/10.1177/0091270003262952
https://doi.org/10.1177/0091270003262952
Autor:
Catherine Perret, E. Sultan, G. Montay, Bernard Lenfant, Marie-Helene Pascual, Vijay O. Bhargava
Publikováno v:
Scandinavian Journal of Infectious Diseases. 34:823-826
Telithromycin is an innovative antibacterial designed for the treatment of community-acquired respiratory tract infections. This study assessed the effect of food on the bioavailability of a single oral dose of telithromycin 800 mg in healthy male su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c226962f8dbd6504e8c67bda87695b
https://doi.org/10.1080/0036554021000026958
https://doi.org/10.1080/0036554021000026958
Publikováno v:
Biopharmaceutics & Drug Disposition. 19:455-463
The pharmacokinetics and dose proportionality of fexofenadine, a new non-sedating antihistamine, and its enantiomers were characterized after single and multiple-dose administration of its hydrochloride salt. A total of 24 healthy male volunteers (31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4daf6712ce755b2645f6a01bf6e6b7c8
https://doi.org/10.1002/(sici)1099-081x(199810)19:7<455::aid-bdd130>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199810)19:7<455::aid-bdd130>3.0.co
Autor:
Dale Yu, Thangam Arumugham, Christina Lippert, Vijay O. Bhargava, Maxine Stoltz, Mark G. Eller, Scott J. Weir
Publikováno v:
Biopharmaceutics & Drug Disposition. 18:645-648
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51babfb489ead4ff7263cef254aa830f
https://doi.org/10.1002/(sici)1099-081x(199710)18:7<645::aid-bdd50>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199710)18:7<645::aid-bdd50>3.0.co
Autor:
Doris K. Robbins, Vijay O. Bhargava, Terry D. Miller, Victor I. Green, Scott J. Weir, Sam J. Hutcheson
Publikováno v:
Biopharmaceutics & Drug Disposition. 18:325-334
MDL 26479 is a new drug undergoing clinical evaluation for the treatment of depression and for memory loss associated with Alzheimer's disease. As part of a dose tolerance trial, the single- (SD) and multiple-dose (MD) pharmacokinetics of MDL 26479 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7424cd9316fc6e66e31efab36b2dbe4
https://doi.org/10.1002/(sici)1099-081x(199705)18:4<325::aid-bdd21>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199705)18:4<325::aid-bdd21>3.0.co
Publikováno v:
Biopharmaceutics & Drug Disposition. 17:753-760
The dose proportionality of deflazacort was assessed following single-dose oral administration at doses of 3, 6, and 36 mg to 24 healthy young adult volunteers. The active metabolite of deflazacort (21-desacetyl deflazacort) was monitored in plasma u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79c48d4fae38b03ff0b045fe750a3a59
https://doi.org/10.1002/(sici)1099-081x(199612)17:9<753::aid-bdd988>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199612)17:9<753::aid-bdd988>3.0.co
Publikováno v:
American Journal of Therapeutics. 3:364-370
Dolasetron, a 5-hydroxytryptamine(3) receptor antagonist, is under investigation for prevention of nausea and vomiting due to chemotherapy. The keto-reduced metabolite of dolasetron has been identified in human plasma and is likely responsible for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::277951cfda2041c49f798f4219b9c439
https://doi.org/10.1097/00045391-199605000-00006
https://doi.org/10.1097/00045391-199605000-00006
Publikováno v:
Pharmaceutical Research. 13:168-172
Purpose. The purpose of this study was to investigate the percutaneous absorption of ketoprofen applied topically to different anatomical sites on the body.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3f3a0b2d6786d8477b8ce2c93fb33b7
https://doi.org/10.1023/a:1016014308638
https://doi.org/10.1023/a:1016014308638
Publikováno v:
Biopharmaceutics & Drug Disposition. 17:43-54
This study was conducted to determine the relative bioavailability of Dilacor XR capsules compared to Cardizem® CD capsules at both low (180 mg d -1 ) and high (540 mg d -1 ) dose levels. Trough and serial plasma samples were obtained and pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a12ac7eb4e3a55423dda7eeb0b115e0
https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co